GSK Cuts 2024 Vaccine Sales Forecast for Second Time This Year

Reuters10-30

Oct 30 (Reuters) - GSK lowered its 2024 vaccine sales forecast for the second time this year on Wednesday, hit by weak demand for its respiratory syncytial virus (RSV) and shingles vaccines.

The British drugmaker now expects 2024 vaccine sales to decrease by low-single digit percentage in turnover. It had previously expected the business to grow by a low to mid-single digit percentage.

The company reported core earnings per share of 49.7 pence on sales of 8.01 billion pounds ($10.41 billion) for the third quarter ended Sept. 30, compared with an EPS of 43.6 pence on sales of about 8 billion pounds in a company-compiled consensus of analyst estimates.

It kept full-year total sales and earnings forecasts unchanged.

"Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new product launches in oncology and HIV," GSK CEO Emma Walmsley said in a statement.

Earlier this month, GSK reached a $2.2 billion settlement to end most of its lawsuits in the United States, claiming that its discontinued version of the heartburn drug Zantac caused cancer.

It took a 1.8 billion pound charge relating to the settlement in the quarter.

($1 = 0.7691 pounds)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

2

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1119966774?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-30 15:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1119966774","market":"uk","top_or_hot":-1,"title":"GSK Cuts 2024 Vaccine Sales Forecast for Second Time This Year","media":"Reuters","content":"<html><head></head><body><p>Oct 30 (Reuters) - GSK lowered its 2024 vaccine sales forecast for the second time this year on Wednesday, hit by weak demand for its respiratory syncytial virus (RSV) and shingles vaccines.</p><p>The British drugmaker now expects 2024 vaccine sales to decrease by low-single digit percentage in turnover. It had previously expected the business to grow by a low to mid-single digit percentage.</p><p>The company reported core earnings per share of 49.7 pence on sales of 8.01 billion pounds ($10.41 billion) for the third quarter ended Sept. 30, compared with an EPS of 43.6 pence on sales of about 8 billion pounds in a company-compiled consensus of analyst estimates.</p><p>It kept full-year total sales and earnings forecasts unchanged.</p><p>&#34;Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new product launches in oncology and HIV,&#34; GSK CEO Emma Walmsley said in a statement.</p><p>Earlier this month, GSK reached a $2.2 billion settlement to end most of its lawsuits in the United States, claiming that its discontinued version of the heartburn drug Zantac caused cancer.</p><p>It took a 1.8 billion pound charge relating to the settlement in the quarter.</p><p>($1 = 0.7691 pounds)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK Cuts 2024 Vaccine Sales Forecast for Second Time This Year</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK Cuts 2024 Vaccine Sales Forecast for Second Time This Year\n</h2>\n\n<h4 class=\"meta\">\n\n2024-10-30 15:20 北京时间&nbsp;&nbsp;&nbsp;<strong>Reuters</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Oct 30 (Reuters) - GSK lowered its 2024 vaccine sales forecast for the second time this year on Wednesday, hit by weak demand for its respiratory syncytial virus (RSV) and shingles vaccines.The ...</p>\n\n<a href=\"\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK.UK","symbol_name":"葛兰素史克","start_time":0,"source_url":"","article_id":"1119966774","we_media_id":"1006801671","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1119966774","pubTimestamp":1730272807,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1006801671","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Oct 30  - GSK lowered its 2024 vaccine sales forecast for the second time this year on Wednesday, hit by weak demand for its respiratory syncytial virus  and shingles vaccines.The British drugmaker now expects 2024 vaccine sales to decrease by low-single digit percentage in turnover. It had previously expected the business to grow by a low to mid-single digit percentage.The company reported core earnings per share of 49.7 pence on sales of 8.01 billion pounds  for the third quarter ended Sept. 3","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"GSK.UK":"葛兰素史克","GSK":"葛兰素史克"},"translate_title":"GSK今年第二次下调2024年疫苗销售预期","themeId":"c0d77e622a6742cf8335299f8317b4b4","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1.1,"GSK.UK":1.1},"content_text":"Oct 30 (Reuters) - GSK lowered its 2024 vaccine sales forecast for the second time this year on Wednesday, hit by weak demand for its respiratory syncytial virus (RSV) and shingles vaccines.The British drugmaker now expects 2024 vaccine sales to decrease by low-single digit percentage in turnover. It had previously expected the business to grow by a low to mid-single digit percentage.The company reported core earnings per share of 49.7 pence on sales of 8.01 billion pounds ($10.41 billion) for the third quarter ended Sept. 30, compared with an EPS of 43.6 pence on sales of about 8 billion pounds in a company-compiled consensus of analyst estimates.It kept full-year total sales and earnings forecasts unchanged.\"Strong growth in specialty medicines helped to offset lower vaccine sales and reflected successful new product launches in oncology and HIV,\" GSK CEO Emma Walmsley said in a statement.Earlier this month, GSK reached a $2.2 billion settlement to end most of its lawsuits in the United States, claiming that its discontinued version of the heartburn drug Zantac caused cancer.It took a 1.8 billion pound charge relating to the settlement in the quarter.($1 = 0.7691 pounds)","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"express","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1119966774"}